GlassScriptPhysician profile
Rosemarie Carrera
NPI 1568413045
$10,491.85
in general payments reported to CMS, 2019-2025
36 companies · $595 in 2025
The $595 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $880 · 2020: $1,828 · 2021: $2,016 · 2022: $2,391 · 2023: $1,588 · 2024: $1,195 · 2025: $595.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,293 · Education: $84.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,292.73 |
| Education | $84.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,895.11 | 2019-2025 | Jardiance, Ofev |
| Astrazeneca Pharmaceuticals LP | $1,879.08 | 2019-2025 | Farxiga, Brilinta |
| E.R. Squibb & Sons, L.L.C. | $1,232.23 | 2019-2025 | Camzyos, Eliquis |
| Merck Sharp & Dohme LLC | $660.05 | 2021-2025 | Verquvo |
| Janssen Pharmaceuticals, INC | $635.32 | 2019-2022 | |
| Glaxosmithkline, LLC. | $515.71 | 2021-2025 | Shingrix |
| Boston Scientific Corporation | $369.44 | 2019-2025 | Resonate El Icd Vr, Zoom Wireless Transmitter, Watchman Flx |
| Pfizer INC. | $303.98 | 2020-2025 | |
| Novartis Pharmaceuticals Corporation | $293.51 | 2019-2025 | |
| Amarin Pharma, INC. | $274.83 | 2019-2022 | |
| Edwards Lifesciences Corporation | $260.64 | 2019-2025 | Sapien 3 Ultra Resilia, Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Lilly USA, LLC | $260.03 | 2022-2025 | Zepbound, Mounjaro |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $250.26 | 2019-2025 | Lifevest |
| Alnylam Pharmaceuticals INC. | $214.76 | 2021-2024 | Amvuttra |
| Novo Nordisk INC | $173.96 | 2023-2025 | Ozempic, Rybelsus |
Show all 36 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rosemarie Carrera listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.